Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

DongKook Life Science Co., Ltd.

동국생명과학303810KOSDAQSector: Pharma & Biotech
₩2,2900.22%Market cap ₩73.2BAs of Sep 1, 2026 close · updated once daily
Market cap
₩73.2B
#912 in KOSDAQ
8.5x
Sector median 16.3x (profitable cos.)
0.56x
Sector median 1.61x
0.0%
Sector median 0.0%
B
Grade B64.4 ptsTop 23% of 2,523 graded stocksMethodology v2.0
Financial strength
61.0/100
Growth momentum
42.8/100
Price attractiveness
87.7/100
Shareholder Return
37.5/100

As of Sep 1, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCurrentCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band B with a total score of 64.4 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩2,200High ₩4,355
Latest close
Price change by period
1W
2.00%
1M
4.50%
3M
18.90%
1Y
43.20%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

61.0/100
How much debt does it carry relative to equity?
65.7%
Sector median 51.6%
Sector lowhighBottom 39.1% in sector
Can it cover what's due within a year?
171.8%
Sector median 191.7%
Sector lowhighBottom 47.2% in sector
How much of revenue becomes profit?
10.0%
Sector median -2.4%
Sector lowhighTop 19.5% in sector
How much did it earn on its own capital?
6.6%
Sector median -4.5%
Sector lowhighTop 22.9% in sector

Source filing: annual report (separate) — view original ↗

2

Growth momentum

42.8/100
How much did revenue grow in a year?
-1.1%
Sector median 6.4%
Sector lowhighBottom 31.1% in sector
Did core profits grow in a year?
9.5%
Sector median 3.6%
Sector lowhighTop 45.6% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

87.7/100
Is the price expensive relative to earnings?
8.5x
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighTop 10.3% in sector
Is the price expensive relative to book value?
0.56x
Sector median 1.61x
Sector lowhighTop 14.4% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Source filing: annual report (separate) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 4 met · 3 not met · 2 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩8.7B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩434M
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not computable

Not computed — required financial data is unavailable

Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
₩434M vs ₩8.7B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
45.1% → 39.6%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
183.9% → 171.8%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
13,932,070 → 31,984,140
Operating margin up
Whether operating income over revenue rose from the prior year.
Met
9.0% → 10.0%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not computable

Not computed — required financial data is unavailable

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (separate) — view original ↗

Grade change history

Jul 23, 2026B

Methodology version change (v2.0 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 14, 2026Source ↗

View in the filings calendar →